Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells Edited by Warren J. Leonard, National Heart, Lung and Blood Institute, Bethesda, MD, and approved October 20, 2016 (received for review June 28, 2016) Adoptive immunotherapy retargeting T cells to CD19 via a chimeric antigen receptor (CAR) is an investigational treatment capable of inducing complete tumor regression of B-cell malignancies when there is sustained survival of infused cells. T-memory stem cells (T SCM ) retain superior potential for long-lived persistence, but challenges exist in manufacturing this T-cell subset because they are rare among circulating lymphocytes. We report a clinically relevant approach to generating CAR + T cells with preserved T SCM potential using the Sleeping Beauty platform. Because IL-15 is fundamental to T-cell memory, we incorporated its costimulatory properties by coexpressing CAR with a membrane-bound chimeric IL-15 (mbIL15). The mbIL15-CAR T cells signaled through signal transducer and activator of transcription 5 to yield improved T-cell persistence independent of CAR signaling, without apparent autonomous growth or transformation, and achieved potent rejection of CD19 + leukemia. Long-lived T cells were CD45RO neg CCR7 + CD95 + , phenotypically most similar to T SCM , and possessed a memory-like transcriptional profile. Overall, these results demonstrate that CAR + T cells can develop long-term persistence with a memory stem-cell phenotype sustained by signaling through mbIL15. This observation warrants evaluation in clinical trials.
adoptive immunotherapy | CAR | IL-15 | T-memory stem cell | T-cell persistence C himeric antigen receptors (CARs) that redirect T-cell specificity to desired tumor-associated antigens (TAAs) (1) are engineered to activate T cells for survival, serial killing, and cytokine production only upon contacting TAA (2) . Adoptive transfer of CAR T cells can achieve durable complete responses in some patients; successful outcomes are associated with engraftment and long-term persistence of CAR T cells (3). Long-term immunosurveillance by persisting CAR T cells is likely key to achieving durable responses in adoptive cell therapy (ACT). Memory T-cell subsets appear to exist along a gradient of differentiation characterized by reciprocal potentials for longevity and effector function (4) . Indeed, adoptively transferred effector CD8 + T cells derived from central memory (T CM ) or naive (T N ) T-cell subsets in murine and nonhuman primate models demonstrated increased therapeutic potential. Thus, T-cell subsets corresponding to an immature state of differentiation are appealing for their potential to provide superior clinical utility (5, 6) .
T-memory stem cells (T SCM ), so far the least differentiated memory T-cell subset identified, can be generated under specific ex vivo culture conditions (e.g., IL-7, IL-15, or small molecules targeting metabolic or developmental pathways) (7) (8) (9) . This memory subset possesses the highest self-renewal capacity and therapeutic potential. Due to superior persistence in the absence of antigen-driven stimulation, T SCM are suggested to be the primary precursors of T-cell memory once antigen is cleared in an immune response (10) . Furthermore, only the frequency of
CD8
+ CD45RA + CCR7 + T SCM -like cells in the infusion product correlated with expansion of CD19-specific CAR T cells (11) . Because T SCM represent only a small percentage (2-3%) of peripheral blood mononuclear cells (PBMCs) (8) , strategies to manufacture T SCM suitable for human applications are essential and under development (9) .
Endogenous and administered T cells receive prosurvival signals through the common cytokine receptor γ-chain, such as those signals mediated by IL-2 and IL-15, independent of native or introduced immunoreceptors. ACT trials have provided exogenous IL-2, which causes dose-limiting toxicities at high doses (12) , whereas low doses may favor peripheral tolerance and regulatory T-cell production (13) . Moreover, IL-2 signaling drives effector T-cell proliferation, promoting terminal differentiation and senescence (14) . Conversely, IL-15 is a prosurvival cytokine that is required for homeostatic maintenance of long-lived CD8 + memory T cells (15), inhibits activation-induced cell death (AICD) (16) , enhances in vivo antitumor activity (17) , and reverses T-cell anergy (18) . High IL15 expression in the tumor microenvironment correlates with elevated infiltration of CD3 + T cells, correlating with improved
Significance
We describe an approach based on cytokine therapeutics to enhance the persistence and effectiveness of T-cell-based immunotherapies using chimeric antigen receptors (CARs). This strategy is effective without the use of high-dose exogenous cytokines that are typically associated with toxicities. Moreover, we report that the persistence of the least differentiated memory T cell, the T-memory stem cell, was promoted by signaling induced by a membrane-bound chimeric IL-15 cytokine-fusion molecule. These findings may contribute to improving the safety and therapeutic efficacy of CAR-based immunotherapies of patients with advanced cancer. survival of patients with colorectal cancer (19) . Moreover, IL-15 is required for the generation of innate-like T cells that participate in immunosurveillance and impede tumor growth (20) . IL-15 is recognized as an immunotherapeutic agent for cancer treatment (21) and is being coinfused with natural killer (NK) or T cells. Monomeric IL-15 is a small unstable protein with a short serum t 1/2 , necessitating supraphysiological dosing to attain in vivo responses (22) . However, physiological transpresentation of IL-15 uses the IL-15 receptor alpha chain (IL-15Rα) (23, 24) . Recombinant soluble IL-15 bound to a recombinant soluble IL-15Rα (referred to as IL-15 complex) augments T-cell antitumor activity (22) , likely due to the qualitatively different signaling achieved upon mimicking transpresentation (25) . Thus, IL-15 complex and ALT-803 (a fusion protein of IL-15 superagonist and IL-15Rα sushi domain) have enhanced the antitumor effect of responding T cells (26, 27) , leading to testing in clinical trials.
To improve the persistence and potential for memory of infused T cells, we sought to harness IL-15 transpresentation by engineering a recombinant tethered variant of IL-15 coexpressed with a second-generation CAR using the Sleeping Beauty (SB) system (28) . The SB system is the most clinically advanced nonviral approach to gene therapy, with recent trials demonstrating promising data related to survival of infused CD19-specific CAR T cells and recipients with B-cell malignancies (29) . Signaling from membrane-bound IL-15 (mbIL15) generated CD19-specific CAR T cells with long-term persistence and superior in vivo antitumor activity. The mbIL15-CAR T cells, despite being recursively cocultured with γ-irradiated activating and propagating cells (AaPCs), exhibited an immature state of differentiation upon antigen removal, leading to sustained in vitro and in vivo persistence without aberrant T-cell proliferation. Indeed, combining expression of mbIL15 with CAR generated T cells that retained memory potential with a CD45RO neg CCR7 + CD95 + T SCM -like phenotype. Because mbIL15-CAR T-cell survival appears independent of antigen, this immunotherapy may be of use not only for treating and preventing relapse when antigen burden is high but also for treating malignant diseases with low or sequestered tumor burdens.
Results

AaPC-Based Platform Generates Numerous T Cells Stably Coexpressing CAR and MbIL15 with Enhanced Signaling via Phosphorylated Signal
Transducer and Activator of Transcription 5. Second-generation CARs mediate signal 1 (via CD3-ζ) and signal 2 (e.g., via CD28) for T-cell activation. We designed mbIL15 for cell-surface expression to provide signal 3 (cytokine stimulation), with and without CARmediated signaling. To generate mbIL15, the full-length native IL-15 peptide was fused to the full-length IL-15Rα sequence via a flexible linker (Fig. 1A) , mimicking presentation of IL-15 in context with IL-15Rα (30, 31) . T cells from PBMCs were coelectroporated with DNA plasmids coding a CD19-specific CAR transposon (designated CD19RCD28), with or without the mbIL15 transposon and with the SB-11 transposase. These cells were propagated with small modifications from previously described methods adapted for human application (28) (SI Appendix, Fig. S1 ). CAR T cells generated with the SB platform were recursively stimulated using K562-derived AaPCs ex vivo to propagate genetically modified T cells in an antigen-dependent fashion to yield a high frequency of cells expressing CAR in the final product. To expand out T cells selectively coexpressing both mbIL15 and CAR after electroporation (Fig. 1B) , we added recombinant soluble IL-21 along with AaPCs during ex vivo coculture to capitalize on the synergistic effect of combining IL-21 with IL-15 upon T-cell proliferation (32) . After four 8-to 10-d cycles of γ-irradiated K562-derived AaPCs (clone 9), CAR expression on the CAR and mbIL15-CAR T cells was not significantly different [94% ± 6% (mean ± SD) and 94% ± 7%, respectively; P = 0.9748, n = 10; Fig. 1B ). Electrotransfer of mbIL15 and CAR from two separate plasmids resulted in coexpression of mbIL15 and CAR at 51% ± 14% (mean ± SD; n = 10) on the antigen-stimulated cells, with minimal expression of mbIL15 alone Expression (%) ( Fig. 1 B and C) . Ex vivo expansion of mbIL15-CAR T cells yielded comparable inferred cell numbers to control CAR T cells (Fig. 1D) . Western blotting confirmed mbIL15 protein expression with the anticipated molecular weight as a fusion protein (SI Appendix, Fig.  S2A ). Validation of mbIL15 function assessed phosphorylation levels of signal transducer and activator of transcription 5 (STAT5). The mbIL15-CAR T cells cultured without exogenous cytokines and CAR T cells exposed to exogenous IL-15 exhibited elevated pSTAT5 expression, relative to CAR T cells without cytokine (Fig. 1E ). Other than low expression of IL-7Rα, mbIL15 expression did not alter the phenotype of ex vivo expanded CAR T cells (Fig. 1F) . The mbIL15-CAR product produced by coculture with AaPCs and IL-21 was predominantly CD8 + CD45RO + T cells expressing moderate levels of CD62L and CD28 (Fig. 1F ). Antigen-specific cytolysis and IFN-γ production remained intact and comparable between CAR and mbIL15-CAR T cells (SI Appendix, Fig. S2 D and E). Thus, clinically large numbers of functional mbIL15-CAR T cells possessing elevated pSTAT5 can be generated. + memory T-cell homeostasis (15), we postulated that mbIL15 could support longlived T SCM in vitro in the absence of immunoreceptor signaling. To assess whether mbIL15 conferred a survival advantage via molecular programming, we compared the mRNA levels of 479 lymphocyte-specific genes between cultured CAR and mbIL15-CAR T cells, both products of four AaPC stimulations, using a digital gene expression analysis with a lymphocyte-specific probe set (SI Appendix, Table S1 ). Surprisingly, we found only four differentially expressed genes (SI Appendix, Table S2), with the difference in IL7RA expression corroborated by cell-surface phenotyping (SI Appendix, Fig. S2C ), indicating no initial overt molecular survival advantage for mbIL15-CAR T cells.
Differences emerged when comparing persisting AWDmbIL15-CAR cells with mbIL15-CAR T cells, where 98 genes were significantly differentially expressed (SI Appendix, Fig. S4 ). Transcripts encoding key regulators of effector differentiation and related cytotoxic molecules showed reduced expression in AWD-mbIL15-CAR T cells: TBX21 (encoding T-BET), PRDM1 (encoding BLIMP-1), IL2RA, IFNG, PRF1, GNLY, GZMH, GZMB, CD11B, and CTLA4. Inversely, a promemory transcriptional profile indicating an immature state of differentiation was present in AWD-mbIL15-CAR T cells: TCF7 (encoding TCF-1), EOMES, BCL2, BACH2, LEF1, BCL6, FOXP1, CCR7, and IL7R (8, 33) ( Fig. 2A and SI Appendix, Fig. S4 ). Some of these transcription factors function in pairs, with graded reciprocal activity controlling effector and memory T-cell differentiation. The ratio of TBET and EOMES is one such pairing, with the ratio lowest in memory T-cell stages (33) . We observed that mbIL15-CAR and AWD-mbIL15-CAR T cells had altered mRNA ratios of TBET and EOMES (20:1-94:1 and 2:1-9:1 TBET/EOMES, respectively), with AWD-mbIL15-CAR T cells having the low ratio associated with memory phenotypes.
The protein expression of specific transcription factors and surface markers associated with the status of T-cell differentiation corroborated the molecular profile of a less differentiated state for AWD-mbIL15-CAR T cells, with increased expression of cell-surface markers associated with memory (IL-7Rα, CD27, and CCR7; Fig. 2 B, C, and F) . CD62L and CD28 expression on AWD-mbIL15-CAR T cells was diminished compared with mbIL15-CAR T cells (Fig. 2 C and F) . AWD-mbIL15-CAR T cells highly expressed CD45RA, but the majority of cells were CD45RA + CD45RO + (Fig. 2 D and F) . However, compared with mbIL15-CAR T cells, AWD-mbIL15-CAR T cells had a significant population of CD45RA + CD45RO neg cells [31% ± 17%, (mean ± SD); P = 0.0233, Student's t test; Fig. 2D ] with nearly all CCR7 + T cells coexpressing CD45RA [89% ± 10% (mean ± SD); Fig. 2E ]. With an observed high coexpression of CD45RA and CD45RO, we defined T-cell memory subsets by CD45RO and CCR7 expression (34, 35) . Thus, it appears that ex vivo numerical expansion (with AaPCs and IL-21) generates predominantly differentiated effector memory mbIL15-CAR T cells with a CD45RO + CCR7 neg phenotype (Fig. 3A) . Upon the withdrawal of antigen and exogenous cytokine, mbIL15 supported two T-cell memory subsets. Differentiated CD45RO neg CCR7 neg AWD-mbIL15-CAR T-cell numbers were maintained, whereas the least differentiated CD45RO neg CCR7 + AWD-mbIL15-CAR T cells increased as much as eightfold, and the remaining two memory subsets significantly declined (Fig. 3A) . All four memory subsets observed in AWD-mbIL15-CAR T cells coexpressed CD95 (Fig. 3B) , thus delineating the CD45RO neg CCR7
+ population as a T SCM subset. The gain of this immature T-cell subset corresponded with improved capacity for IL-2 production (Fig.  3C) , because 2-8% of mbIL15-CAR and 25-46% of AWDmbIL15-CAR T cells produced IL-2 in response to stimulation, a cardinal feature of memory cells (35) . These data support our contention that mbIL15-CAR T cells contain and/or produce T SCM .
To determine whether the promotion of T SCM was due to mbIL15, we conducted a modification of the withdrawal assay comparing AWD-mbIL15-CAR T cells with AWD-CAR T cells that had IL-2 or IL-15 complex support during antigen withdrawal (SI Appendix, Fig. S5A ). CD45RA expression was uniformly high among all treatment groups, whereas CCR7 expression was only high on AWD-mbIL15-CAR T cells (69% ± 23%), which also had significantly reduced Annexin V levels compared with control CCR7 + AWD-CAR T cells cultured with soluble IL-2 or IL-15 complex (P < 0.05; SI Appendix, Fig. S5 B-E) . Thus, mbIL15 supports the survival of CD45RO neg CCR7
+ T cells, thereby supporting the persistence and/or emergence of T SCM in our system. -CAR-firefly luciferase (ffLuc)] were administered to mice without tumor or exogenous cytokine support and monitored for 48-50 d. Control CAR T cells did not persist, whereas mbIL15-CAR T cells persisted without apparent autonomous growth and were detected primarily in the bone marrow (BM) and spleen (Fig. 4 A and B and SI Appendix, Fig.  S6A ). Thus, it appears that mbIL15 provides sufficient support to sustain T-cell persistence in a CAR-independent manner.
The phenotype and ability of mbIL15-CAR T cells to redirect specificity to CD19 were evaluated 48 Recovered T cells exhibited tissue-specific distribution with reciprocal expression of CD45RO and CCR7, with the highest levels observed in BM and peripheral blood, respectively (Fig.  4C ). T-cell differentiation in the peripheral blood and spleen recapitulated our in vitro observations of the preferential persistence of CD45RO neg CCR7 + T cells, whereas the BM contained the highest proportion of more differentiated CD45RO + CCR7 neg T cells (Fig. 4D ). Similar to in vitro observations, T cells in the blood expressed moderate levels of CAR and reduced levels of cell-surface mbIL15 (SI Appendix, Fig. S6 B and C) . After ex vivo numeric expansion, T cells from these tissues retained their antigen-specific function and produced IFN-γ in response to CD19 + targets (SI Appendix, Fig. S6D ). Together, these data suggest that mbIL15-CAR T cells persist long term in vivo, with a substantial subset exhibiting a clinically desirable T SCM phenotype and continuing to demonstrate specificity for CD19 TAA.
We also evaluated the safety of long-term mbIL15-CAR T-cell persistence, focusing on potential for transformation or autonomous proliferation. The mbIL15-CAR T cells were maintained in continuous in vitro culture for up to 2 y in the absence of antigen restimulation and exogenous cytokine. These T cells did not demonstrate aberrant unrestricted proliferation, and all samples tested (n = 4) maintained a normal karyotype as well as polyclonal Vα/Vβ repertoires (SI Appendix, Fig. S7 ). In vivo studies of mice with longterm (125 d after T-cell infusion) engraftment of mbIL15-CAR T cells in the absence of tumor demonstrated no host toxicity and no evidence of aberrant proliferation of infused genetically modified T cells. Indeed, splenomegaly was not observed, and <1% of human CD3 + cells were observed at day 125 (SI Appendix, Fig. S8 ).
MbIL15-CAR T Cells Prevent Leukemia Engraftment and Sustain
Persistence After Clearance of Tumor. We assessed survival of mbIL15-CAR T cells in a model of minimal residual disease (MRD or low TAA burden), where adoptively transferred T cells may not immediately encounter and be stimulated by TAA, such as CD19. This assessment was achieved using a model to mimic MRD whereby CAR T cells expressing ffLuc and mbIL15-CARffLuc T cells were engrafted in NSG mice, (Fig. 5 A and C) . The mbIL15-CAR T cells displayed potent antitumor activity (Fig. 5B) , with no tumor (<0.5% of CD19 + cells) detected by flow cytometry in the BM, spleen, or peripheral blood (Fig. 5C) . In another experiment, mice receiving mbIL15-CAR T cells had improved survival: 43% at 98 d compared with 100% mortality in all other treatments by day 34 (Fig. 5D ). These data indicate that mbIL15-CAR T cells were capable of engrafting in the absence of CD19 antigen or exogenous cytokine, mounting an antitumor response in a low TAA environment and persisting after tumor clearance, thereby making these cells more therapeutically effective in mice than conventional CAR T cells.
MbIL15-CAR T Cells Reject Established Leukemia and Sustain
Persistence After Clearance of Tumor. Recently, it was reported that the IgG4-Fc extracellular domain within CAR structures, such as CD19RCD28 in our initial clinical trials, may bind to innate Fcγ receptors (FcγRs), leading to deleterious clearance and reduced efficacy of infused CAR T cells (36) . We hypothesized that mbIL15 can continue to support CAR T-cell persistence and act additively with an improved CAR design to augment antitumor efficacy further. Another CAR was engineered (referred as *CAR) with a mutation to eliminate FcγR binding. We reassessed mbIL15 ± -CAR and mbIL15
± -*CAR T-cell persistence and antitumor efficacy using a model of established leukemia. NSG mice were injected with ffLuc + NALM-6, followed 6 d later by genetically modified T cells (not modified with ffLuc). The *CAR T cells demonstrated greater antitumor activity than did CAR T cells, significantly increasing survival (P = 0.0007; Fig. 6 A and B) . The *CAR T-cell persistence at the experimental end point was low (Fig. 6C) mbIL15-*CAR T cells demonstrated superior antitumor activity, reducing tumor burden to background levels, with tumor flux significantly lower than in mice treated with *CAR T cells (P = 0.006, two-tailed Student's t test, day 26 after T-cell administration). The *CAR T cells induced only temporary tumor regression, followed by aggressive relapse (Fig. 6A) . Notably, 83% of mice treated with mbIL15-*CAR T cells exhibited tumor elimination, because no responders relapsed during the experiment and flow cytometry corroborated that these mice were tumor-free in the BM, spleen, and peripheral blood ( Fig. 6 A and C). Some mice in this group began dying 28 d after T-cell injection with no tumor measured by bioluminescence and flow cytometry. Likely, these deaths were from xenograft-versus-hostdisease, as noted by others using cytokine-producing CAR T cells (37) . To compensate, we report disease-free survival, rather than overall survival, which was significantly greater for mice treated with mbIL15-*CAR T cells compared with *CAR T cells (P = 0.007; Fig. 6B ). In vivo persistence of genetically modified T cells was only slightly enhanced by the substitution of CAR with *CAR. Substantial improvement was made when mbIL15 was coexpressed with *CAR, whereby these mice did not bear tumor at the time of sampling (Fig. 6C) . These data indicate that mbIL15-*CAR T cells were capable of engrafting, mounting an antitumor response in an environment with abundant TAA, and persisting after tumor clearance with no evidence of relapse, thereby making these cells more therapeutically effective in mice irrespective of the potency of the CAR.
Discussion
Adoptive transfer of CD19-specific CAR T cells has demonstrated significant antitumor effects as an investigational treatment for leukemias and lymphomas, in which therapeutic potential appears to correlate with sustained in vivo persistence (11, (38) (39) (40) (41) . Moreover, elevated IL15 expression in the tumor microenvironment correlates with improved patient survival (19) . We demonstrated that, in contrast to T cells solely expressing a second-generation CD19-specific CAR, coexpression of CAR with a tethered variant of IL-15 augmented T-cell survival in vitro and in vivo that resulted in superior antitumor effects and was associated with the outgrowth of T SCM .
Thus, it appears that mbIL15 mimics the transpresentation of endogenous IL-15, signaling via STAT5, without leading to aberrant proliferation. Second-generation CARs are designed with modular costimulatory endodomains to coordinate two signals to mediate CAR-dependent T-cell activation (42) , but this design may not be sufficient in all cases. When TAA is abundant, as when treating relapsed B-cell malignancies, the CAR design may be sufficient to mitigate malignant disease. Striking results have been observed in several second-generation CAR T-cell clinical trials that treated acute lymphoblastic leukemia, where complete responses were observed in 70-90% of patients (43) (44) (45) . However, long-term results were not as durable, because the overall survival was reported to be 65-78% at 6-12 mo (43) (44) (45) . In parallel, our mice with established leukemia treated with *CAR T cells showed 50% initial remission but 100% eventually relapsed. This is in contrast to no mice that relapsed following infusion of mbIL15-*CAR T cells (Fig. 6) . This difference suggests that an mbIL15-mediated signal 3 can bolster the effects of the more potent CAR designs, and may augment the T-cell response by inhibiting AICD (16) . Alternatively, mbIL15 may favor the persistence of T cells with a less differentiated state throughout the multiple activation events of an antitumor response. Conversely, when TAA is limited, such as with MRD, then activation solely through the CAR may be insufficient to maintain persistence (41) . Indeed, in our model with a low leukemia burden, the survival of infused T cells and mice depended on coexpression of mbIL15 with CAR. The mbIL15-CAR T cells persisted in the absence of CD19 TAA, presumably due to sustained STAT5 phosphorylation. These observations agree with studies where engraftment was enhanced by T cells engineered to (i) express constitutively active STAT5 (46); (ii) express a chimeric cytokine receptor mediating constitutive signaling through CD122 (47); (iii) secrete monomeric recombinant IL-15 (37, 48) ; and (iv) express miR155, which increases AKT and STAT5 signaling (49) . Thus, it appears that coordinated signaling with mbIL15 and CAR provides a pathway to improving antitumor effects across a spectrum of tumor burden. The approach of combining signals 1 and 2 via CAR with signal 3 from mbIL15 may be preferred to coinfusing CAR T cells with soluble recombinant IL-15 due to toxicity (50) . Differentiation status is a predictor of T-cell persistence with therapeutic preference given to a biological product that has not entered into terminal differentiation or replicative senescence (8). It is not clear whether adoptively transferred CAR T cells modified to receive additional costimulation (e.g., via constitutively active pSTAT5 or secreted cytokines) can modulate their activation to form or maintain memory, or if they remain perpetually supraphysiologically activated, which may raise concerns for long-term safety. We observed that mbIL15-CAR T cells harvested from TAA-free mice after 50 d persisted in a spectrum of differentiation states, including a substantial population exhibiting immature differentiation, delineated as CD45RO neg CCR7 + and consistent with the T SCM phenotype (Fig. 4) . The in vivo observations recapitulated the in vitro data from long-term cultured AWD mbIL15-CAR T cells (Fig. 3 ) that were CD45RA + and coexpressed CD27 and IL-7Rα, had elevated TCF-1, and were capable of IL-2 production (Fig. 2) . Some transcription factors function in pairs, with graded reciprocal activity controlling effector and memory T-cell differentiation. The ratio of TBET and EOMES is one such pairing, with the ratio lowest in early memory T-cell differentiation states (33, 51) , a pattern observed in mbIL15-CAR and AWD-mbIL15-CAR T cells. Long-lived CAR T cells genetically modified to secrete monomeric IL-15 had increased expression of CD45RA, and a small subset of CD45RA +
CCR7
+ cells (∼6%) persisted in the spleen after an antitumor response (37) . We observed that ∼25% of engrafted splenic T cells were CD45RO neg CCR7
+ (Fig. 4) . In contrast to our results, antigen-specific T cells modified to express constitutively active STAT5 demonstrated an effector phenotype 20 d after infusion characterized by elevated T-BET levels, effector molecule expression, and diminished IL-2 production (52). However, another study that used transgenic (Tg) mice expressing a constitutively activated form of STAT5 in the T-lymphocyte compartment showed an increased number of CD8 + T cells phenotypically similar to memory-like or homeostatically proliferating T cells (53) . This finding suggests that mbIL15-mediated activation of the STAT5 pathway enables the emergence of the early memory phenotype we observed. Thus, it appears that mbIL15 provides signaling to CAR T cells that delivers an advantage over other approaches to STAT5-mediated activation, possibly due to its ability to generate T SCM .
One concern for extensively ex vivo-propagated T cells is the potential for generating an exhausted product with limited antitumor efficacy. Unlike the protective effects of chimeric 4-1BB costimulation, chimeric CD28 apparently exacerbates exhaustion induced by chronic CAR signaling, whether by high tumor loads, ex vivo numeric expansion, or antigen-independent mechanisms (54) . Exhausted CAR T cells express higher levels of inhibitory receptors (e.g., PD-1, TIM-3, LAG-3) and increased exhaustionassociated transcription factors (e.g., T-bet, Blimp-1). Such cells exhibit poor production of IL-2 and IFN-γ, increased expression of CD25, and decreased levels of CD27 and CD127 (54) . The AWD-mbIL15-CAR T cells possessed reciprocal features: reduced LAG3 and CTLA4 transcripts (SI Appendix , Fig. S4 ); low T-BET, BLIMP-1, and IL2RA expression; and increased CD27 and CD127 expression (Fig. 2) . The AWD-mbIL15-CAR T cells also possessed antigen-dependent IFN-γ production (SI Appendix, Fig. S3 ), enhanced IL-2 production (Fig. 3) , and antigen-independent persistence (SI Appendix, Fig. S3 ). Our data indicate that mbIL15 maintains a memory subset of CAR T cells consistent with T SCM that also preserve their CAR-mediated function. Thus, although chimeric CD28 costimulation participates in T-cell activation, differentiation, and exhaustion, it appears that IL-15 signaling may block these downstream effects. Additional experiments will be needed to understand this interaction and the possible effect of mbIL15 on activating CAR T cells via chimeric CD137.
The cytokines IL-7 and IL-15 appear integral to generating CD45RA +
+ early memory populations (7). We demonstrated that mbIL15, and not IL-2 or soluble IL-15 complex, helps preserve the CCR7 + subset (SI Appendix, Fig. S5 ). Different signaling patterns are mediated between soluble and transpresented IL-15 (25) ; thus, the surface expression level and specific signaling induced by the tethered mbIL15 may provide necessary and sufficient signaling to maintain the CCR7 + T-cell subset. This finding contrasts with a report that both soluble and membrane-bound IL-15Ra complexes with IL-15 (but not soluble monomeric IL-15) supported expansion of CD62L + and CCR7
+ central memory antigen-specific T cells using an in vitro cell-based cytokine production system (55) . Soluble cytokines present at supraphysiological levels may induce T-cell differentiation (56) , which may have been a factor contributing to the observations within our in vitro system. Nonetheless, although mechanisms for generating less differentiated T cells remain to be elucidated fully, we show that these subsets can arise in our system from signal 3 transmitted by mbIL15. This preserved persistence potential appears analogous to early memory, and, as demonstrated by others, the least differentiated subsets of adoptively transferred T cells exhibit the greatest therapeutic potential (7, 8) .
Bona fide T SCM (CD45RA
have been generated in vitro from T N cells using a glycogen synthase kinase 3β-inhibitor to activate the WNT pathway, combined with IL-2 (8) or IL-7 and IL-21 (9) cytokine supplementation. T SCM , albeit CD45RO + , have also been produced using IL-7 and IL-15 ex vivo (7). Our T SCM population of mbIL15-CAR T cells (CD45RA + CD45RO neg CCR7 + CD122 + CD95 + ) had exposure to IL-21-and IL-15-mediated signaling during ex vivo numeric expansion, and then only to IL-15 (in the form of mbIL15) signaling, during the 65-d antigen and cytokine withdrawal assay to generate AWD-mbIL15-CAR T cells. Furthermore, T SCM recovered from mice apparently only had access to mbIL15. Although it cannot be ruled out that IL-21 could have a programming effect on the cells, it was primarily upon removal of IL-21 and antigen (presented by AaPCs) that we observed the promotion and outgrowth of the mbIL15-CAR T SCM subset. Previously, it has been shown that IL-15 alone could produce a small population of T SCM , but combination with IL-7 improved these numbers (7, 57) . Thus, we contend that the desired T SCM subset can arise solely upon IL-15-mediated signaling as induced by mbIL15.
In contrast to observations of IL-7-and IL-15-generated T SCM with no apparent up-regulation of the WNT pathway (7), we noted increased expression of genes in this pathway (TCF7, LEF1, and AXIN2; SI Appendix, Fig. S4 ), which are regulated by Akt (51, 58) . Moreover, because AXIN2 is a direct target of the WNT pathway through TCF-1 and LEF-1 activity, its up-regulation suggests that WNT signaling is active in AWD-mbIL15-CAR T cells. Furthermore, Akt signal strength regulates the WNT pathway, where weaker signaling sustains a memory phenotype (51) , suggesting that molecular pharmacology may be beneficial when using exogenous cytokines or priming conditions that can strongly activate Akt (8, 9, 59) . Moreover, our data demonstrated the promotion of an mbIL15-CAR T SCM -like subset, suggesting that mbIL15 only weakly activates Akt.
Our study has benefited from an approach to genetically modifying a population of T cells, which has appeal for the manufacture of a clinical grade mbIL15-CAR product. In our antigen and cytokine withdrawal assay, we observed a decline in CD45RO +
+ T-cell numbers with a concomitant increase of the CD45RO neg CCR7
+ T SCM pool. This finding may be due to cell death in the CD45RO +
+ subpopulation with proliferation in the CD45RO neg CCR7
+ subset. However, this process appears unlikely, considering reports that IL-15 is critical to supporting T CM cells (60) . Alternatively, it has been shown that a proportion of sorted T CM cells dedifferentiated to a CD45RO neg CCR7 + phenotype in the presence of IL-7 and IL-15 and in the absence of antigen (57) . At this time, we find dedifferentiation to be a plausible and likely predominant mechanism generating the mbIL15-CAR T SCM -like cells rather than preferential propagation of small numbers of T SCM in the genetically modified founder population.
Antigen-experienced T cells can drive precocious differentiation of T N cells within mixed populations that impairs antitumor immunity (61) . In our system, we modify, ex vivo expand, and infuse cell products containing a mixed grouping of memory T-cell subsets. The heterogeneous mbIL15-CAR T-cell cultures show the emergence of T SCM both in vitro and in vivo when removed from antigen. This preserved potential may have clinical appeal, because the least differentiated T-cell subset mediated the greatest therapeutic potential (7, 8) . It is currently not feasible to treat patients with naturally occurring T SCM due to their low circulating frequency; thus, identification of strategies to generate, or preserve the potential of, clinically relevant numbers of genetically modified T SCM would likely contribute to the advancement of CAR T-cell-based therapies. The results presented herein show that, in our system, mbIL15 promoted a T SCM -like population of CAR-modified T cells, and thus bolster the rationale for using mbIL15 in further developing clinically compliant strategies to augment this desirable T-cell subset in immunotherapy infusion products.
Supporting T-cell longevity via IL-15 may have risk, because chronic high exposure to IL-15 could cause aberrant T-cell proliferation or toxicities. In humans, dysregulated IL-15 production, elevated serum levels, or abnormal IL-15 signaling has been associated with autoimmune disease and may be involved in the pathogenesis of large granular lymphocytic leukemia (62) and cutaneous T-cell lymphoma (63) . This concern is heightened, given that Tg mice engineered to overexpress IL-15 developed leukemia (64, 65) ; another form of mbIL15 led to autonomous growth of NK cells (66) ; a T-cell clone modified to secrete IL-15 led to aberrant autonomous T-cell growth (67) ; and in IL-15Rα-IL-15 double-Tg mice, cis IL-15Rα expression on leukemic CD8 T cells was required for the development of uncontrolled lymphoproliferation (65) . Additionally, it has been reported that excessive IL-15 can cause malignant transformation of CD4 T cells via inhibition of a negative autoregulatory loop (63) . The common thread among these studies is T-cell supraphysiological activation from elevated levels of IL15-Rα and/or soluble IL-15. However, we provide an alternative to IL-15 hyperstimulation. We demonstrated that mbIL15-CAR T cells had submaximal pSTAT5 levels relative to control CAR T cells stimulated with exogenous IL-15 and that these cells attained a desired less differentiated phenotype. In other studies, T cells constitutively expressing activated STAT5 demonstrated enhanced persistence but not transformation (46) , despite an activated effector phenotype (46, 52) . In summary, contrasting the previous studies (62, 63, 65, 67) , our assessments of AWDmbIL15-CAR T cells did not demonstrate (i) log growth in vitro, (ii) uncontrolled expansion in vivo, (iii) aneuploidy, (iv) a homogeneous differentiated or activated population, or (v) clonal outgrowth, all of which predict favorable human application of mbIL15-CAR T cells. It is significant that our study demonstrated long-term engraftment of T cells without dysregulated proliferation or activation and no phenotypic, functional, or chromosomal anomalies.
In summary, we demonstrate that CAR T cells can be engineered to coexpress a tethered form of IL-15 that supports in vivo persistence and maintenance of an immature state of differentiation through in vitro culture and in vivo engraftment. The signal 3 provided by mbIL15 alone gave rise to CD45RO neg CCR7
+ T SCM despite multiple rounds of ex vivo T-cell activation. Our observations suggest that mbIL15 may provide a desired signaling enabling infused T cells to prolong persistence, thereby providing durable immune surveillance and therapeutic potential.
Methods
Animal studies were performed in accordance with guidelines set forth by the M. D. Anderson Cancer Center Institutional Animal Care and Use Committee (A3343-01, protocol 03-06-04333). Human mononuclear cell buffy coats from anonymized healthy donors were obtained from a US Food and Drug Administration-approved vendor or blood bank (Key Biologics or the Gulf Coast Regional Blood Center). Cell lines and their propagation, genetic modification of T cells using SB, immunophenotyping, chromium release assay, and BLI were previously described (28, (68) (69) (70) (71) . Detailed information about experimental procedures, antibodies, mice, and statistical analyses can be found in SI Appendix, Materials and Methods.
